Floatz logo

Gevokizumab

Colon Cancer

NSABP Foundation Incmonoclonal_antibodyPhase 2Active
CCC
48/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
65/ 100

Competitive context

157 Active assets in the Colon Cancer cohort.

Asset / SponsorPhaseRating
FLUOROURACILUM
Akeso
Phase 4A
Irinotecan
Fudan University
Phase 3BBB
Floxuridine
City of Hope Medical Center
Phase 2BBB
FLUOROURACILUM
Akeso
Phase 4BB
Eloxatin
Sun Yat-sen University
Phase 3BB

View all 50 →

Same molecule, other indications

Gevokizumab is also rated in:

gastroesophageal cancerDormant
CC
Indicative ·
44 / 100
View asset →
renal cell carcinomaDormant
CC
Indicative ·
40 / 100
View asset →
colorectal cancerDormant
C
Indicative ·
39 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →